TY - JOUR
T1 - Early generated B1 B cells with restricted BCRs become chronic lymphocytic leukemia with continued c-Myc and low Bmf expression
AU - Hayakawa, Kyoko
AU - Formica, Anthony M.
AU - Brill-Dashoff, Joni
AU - Shinton, Susan A.
AU - Ichikawa, Daiju
AU - Zhou, Yan
AU - Morse, Herbert C.
AU - Hardy, Richard R.
N1 - Funding Information:
We thank Carlo M. Croce for providing Eμ-hTCL1 transgenic mice. CD3γδ knockout mice originally made by C. Terhorst were provided by D. Kappes. Eμ-Bcl-1 transgenic mice provided by M. Smith. We thank Y. Nakao for analysis of tumor mice, L. Wen for hTCL1 cytoplasmic staining, and A. Purdy for photomicrograph of cultured tumor B cells. Also, we acknowledge several Fox Chase Cancer Center (FCCC) Facilities (Lab Animal, Flow Cytometry, DNA Sequencing, and Histopathology) for technical support and K. Campbell for comments on the manuscript. This work was supported by National Institutes of Health (NIH) grants R01 CA129330 (K. Hayakawa), R01 AI049335 (K.H. Hayakawa), and R01 AI11320 (R.R. Hardy), and the FCCC Blood Cell Development and Cancer Keystone program, and in part by the Intramural Research Program of the NIH, National Institute of Allergy and Infectious Diseases. The authors declare no competing financial interests.
Publisher Copyright:
© 2016 Hayakawa et al.
PY - 2016/12/12
Y1 - 2016/12/12
N2 - In mice, generation of autoreactive CD5+ B cells occurs as a consequence of BCR signaling induced by (self)-ligand exposure from fetal/neonatal B-1 B cell development. A fraction of these cells self-renew and persist as a minor B1 B cell subset throughout life. Here, we show that transfer of early generated B1 B cells from Eμ-TC L1 transgenic mice resulted in chronic lymphocytic leukemia (CLL) with a biased repertoire, including stereotyped BCRs. Thus, B1 B cells bearing restricted BCRs can become CLL during aging. Increased anti-thymocyte/Thy-1 autoreactive (ATA) BCR cells in the B1 B cell subset by transgenic expression yielded spontaneous ATA B-CLL/lymphoma incidence, enhanced by TC L1 transgenesis. In contrast, ATA B-CLL did not develop from other B cell subsets, even when the identical ATA BCR was expressed on a Thy-1 low/null background. Thus, both a specific BCR and B1 B cell context were important for CLL progression. Neonatal B1 B cells and their CLL progeny in aged mice continued to express moderately up-regulated c-Myc and down-regulated proapoptotic Bmf, unlike most mature B cells in the adult. Thus, there is a genetic predisposition inherent in B-1 development generating restricted BCRs and self-renewal capacity, with both features contributing to potential for progression to CLL.
AB - In mice, generation of autoreactive CD5+ B cells occurs as a consequence of BCR signaling induced by (self)-ligand exposure from fetal/neonatal B-1 B cell development. A fraction of these cells self-renew and persist as a minor B1 B cell subset throughout life. Here, we show that transfer of early generated B1 B cells from Eμ-TC L1 transgenic mice resulted in chronic lymphocytic leukemia (CLL) with a biased repertoire, including stereotyped BCRs. Thus, B1 B cells bearing restricted BCRs can become CLL during aging. Increased anti-thymocyte/Thy-1 autoreactive (ATA) BCR cells in the B1 B cell subset by transgenic expression yielded spontaneous ATA B-CLL/lymphoma incidence, enhanced by TC L1 transgenesis. In contrast, ATA B-CLL did not develop from other B cell subsets, even when the identical ATA BCR was expressed on a Thy-1 low/null background. Thus, both a specific BCR and B1 B cell context were important for CLL progression. Neonatal B1 B cells and their CLL progeny in aged mice continued to express moderately up-regulated c-Myc and down-regulated proapoptotic Bmf, unlike most mature B cells in the adult. Thus, there is a genetic predisposition inherent in B-1 development generating restricted BCRs and self-renewal capacity, with both features contributing to potential for progression to CLL.
UR - http://www.scopus.com/inward/record.url?scp=85008517897&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85008517897&partnerID=8YFLogxK
U2 - 10.1084/jem.20160712
DO - 10.1084/jem.20160712
M3 - Article
C2 - 27899442
AN - SCOPUS:85008517897
SN - 0022-1007
VL - 213
SP - 3007
EP - 3023
JO - Journal of Experimental Medicine
JF - Journal of Experimental Medicine
IS - 13
ER -